We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · February 04, 2021

Selective Estrogen Receptor Degrader Elacestrant in ER-Positive, HER2-Negative Advanced Breast Cancer

Journal of Clinical Oncology


Additional Info

Disclosure statements are available on the authors' profiles:

Journal of Clinical Oncology
Phase I Study of Elacestrant (RAD1901), a Novel Selective Estrogen Receptor Degrader, in ER-Positive, HER2-Negative Advanced Breast Cancer
J. Clin. Oncol 2021 Jan 29;[EPub Ahead of Print], A Bardia, V Kaklamani, S Wilks, A Weise, D Richards, W Harb, C Osborne, R Wesolowski, M Karuturi, P Conkling, RG Bagley, Y Wang, MG Conlan, P Kabos

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading